Skip to main content
Premium Trial:

Request an Annual Quote

Bruker AXS Earns Additional $8M as Underwriters Exercise Over-Allotment Option

NEW YORK, Jan. 9 - Bruker AXS on Wednesday said that the underwriters of its initial public offering have exercised their over-allotment option and purchased an additional 1.35 million shares of common stock at $6.50 per share.


The action yields the X-ray systems developer roughly $8 million. The purchase also brings Bruker's IPO to 10.35 million shares with a market cap of approximately $62 million.


Bruker AXS last month earned $53 million after an IPO let loose 9 million shares of common stock at $6.50 apiece.


The two main underwriters were UBS Warburg and Thomas Weisel Partners. CIBC World Markets, SG Cowen, and Robert W. Baird & Co. were co-managers.


Bruker AXS develops and sells advanced systems for crystallography, X-ray diffraction, and X-ray fluorescence. It has development partnerships with GeneFormatics and an equity stake in Integrative Proteomics, and acquired the X-ray crystallography division of Delft Instruments in March.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.